Expression of recombinant G-CSF receptor domains and their inhibitory role on G-CSF function

Hamid Bakherad , Neda Setayesh, Seyed Latif Mousavi Gargari, Walead Ebrahimizade, Faranak Mavandadnejad, Elnaz Faghfuri, Soheila Ebrahimi, Mohammad Heiat, Mona Shahpari, Zargham Sepehrizadeh



Background and purpose: Granulocyte colony-stimulating factor (G-CSF) is routinely used in combination with chemotherapy to battle neutropenia. However, studies suggest that this chemokine may increase the risk of metastasis and malignancy in many cancers. To counteract the adverse effects of G-CSF in cancer, antibodies have been used to block its action. However, antibodies are large and complex molecules which makes their production expensive. Thus in this study, we aim to construct different structure variants of the  G-CSF receptor containing different domains and select the best variant that prevents the adverse actions of this chemokine. These novel structures are smaller than antibodies and easier to produce.

Experimental approach: Different domains of the G-CSF receptor were designed and cloned into the pET28a expression vector. These recombinant receptor subunits were then expressed in Escherichia coli and purified using standard affinity chromatography techniques. Interaction of recombinant receptor subunits with G-CSF was assessed using enzyme-linked immunosorbent assay and NFS60 cells.

Findings / Results: Two recombinant receptor subunits containing D1 + D2 + D3 domains and D2 domain showed the strongest inhibitory activity to G-CSF.

Conclusion and implications: These novel recombinant receptor variants could be candidates for further studies in the development of novel therapeutics.


G-CSF antagonist; G-CSF-R domains; NFS60.

Full Text:



Kadota R, Koda M, Kawabe J, Hashimoto M, Nishio Y, Mannoji C, et al. Granulocyte colony-stimulating factor (g-csf) protects oligpdendrocyte and promotes hindlimb functional recovery after spinal cord injury in rats. PloS One. 2012;7(11):e50391,1-12.

DOI: 10.1371/journal.pone.0050391.

Klocke R, Kuhlmann MT, Scobioala S, Schabitz WR, Nikol S. Granulocyte colony-stimulating factor (G-CSF) for cardio-and cerebrovascular regenerative applications. Curr Med Chem. 2008;15(10):968-977.

DOI: 10.2174/092986708784049649.

Hartung T. Granulocyte colony-stimulating factor: its potential role in infectious disease. AIDS. 1999;13(2):S3-9.

Bakherad H, Gargari SLM, Sepehrizadeh Z, Aghamollaei H, Taheri RA, Torshabi M, et al. Identification and in vitro characterization of novel nanobodies against human granulocyte colony-stimulating factor receptor to provide inhibition of G-CSF function. Biomed Pharmacother. 2017;93:245-254.

DOI: 10.1016/j.biopha.2017.06.025.

Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A. 2009;106(16):6742-6747.

DOI: 10.1073/pnas.0902280106.

Yang X, Liu F, Xu Z, Chen C, Wu X, Li G, et al. Expression of granulocyte colony stimulating factor receptor in human colorectal cancer. Postgrad Med J. 2005;81(955):333-337.

DOI: 10.1136/pgmj.2004.024646.

Tachibana M, Miyakawa A, Tazaki H, Nakamura K, Kubo A, Hata J, et al. Autocrine growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor. Cancer Res. 1995;55(15):3438-3443.

Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T, Qu X, et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A. 2010;107(50):21248-21255.

DOI: 10.1073/pnas.1015855107.

Mueller MM, Fusenig NE. Constitutive expression of G-CSF and GM-CSF in human skin carcinoma cells with functional consequence for tumor progression. Int J Cancer. 1999;83(6):780-789.

DOI: 10.1002/(sici)1097-0215(19991210)83:6<780:: aid-ijc14>;2-c.

Cornish AL, Campbell IK, McKenzie BS, Chatfield S, Wicks IP. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(10):554-559.

DOI: 10.1038/nrrheum.2009.178.

Araki K, Kishihara F, Takahashi K, Matsumata T, Shimura T, Suehiro T, et al. Hepatocellular carcinoma producing a granulocyte colony-stimulating factor: report of a resected case with a literature review. Liver Int. 2007;27(5):716-721.

DOI: 10.1111/j.1478-3231.2007.01468.x.

Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157(2):220-233.

DOI: 10.1111/j.1476-5381.2009.00190.x.

Fukunaga R, Ishizaka-Ikeda E, Pan CX, Seto Y, Nagata S. Functional domains of the granulocyte colony-stimulating factor receptor. EMBO J. 1991;10(10):2855-2865.

Layton JE, Hall NE. The interaction of G-CSF with its receptor. Front Biosci. 2006;11:3181-3189.

DOI: 10.2741/2041.

Iida S, Kohro T, Kodama T, Nagata S, Fukunaga R. Identification of CCR2, flotillin, and gp49B genes as new G-CSF targets during neutrophilic differentiation. J Leukoc Biol. 2005;78(2):481-490.

DOI: 10.1189/jlb.0904515.

Mueller MM, Peter W, Mappes M, Huelsen A, Steinbauer H, Boukamp P, et al. Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Am J Pathol. 2001;159(4): 1567-1579.

DOI: 10.1016/S0002-9440(10)62541-2.

Kasuga I, Makino S, Kiyokawa H, Katoh H, Ebihara Y, Ohyashiki K. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer. 2001;92(9):2399-2405.

DOI: 10.1002/1097-0142(20011101)92:9<2399::aid-cncr1588>;2-w.

Sato K, Terada K, Sugiyama T, Sugiyama T, Masuda H, Kakinuma H, et al. Granulocyte colony-stimulating factor produced by bladder carcinoma of a patient with leukemoid reaction did not affect proliferation of the tumor cells. J Urol. 1994;151(6):1687-1690.

DOI: 10.1016/s0022-5347(17)35345-4.

Baba M, Hasegawa H, Nakayabu M, Shimizu N, Suzuki S, Kamada N, et al. Establishment and characteristics of a gastric cancer cell line (HuGC-OOHIRA) producing high levels of G-CSF, GM-CSF, and IL-6: the presence of autocrine growth control by G-CSF. Am J Hematol. 1995;49(3): 207-215.

DOI: 10.1002/ajh.2830490306.

Lee MC, McCubbin JA, Christensen AD, Poole DP, Rajasekhar P, Lieu T, et al. G-CSF receptor blockade ameliorates arthritic pain and disease. J Immunol. 2017;198(9):3565-3575.

DOI: 10.4049/jimmunol.1602127.

Qiu XQ, Wang H, Cai B, Wang LL, Yue ST. Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting. Nat Biotechnol. 2007;25(8): 921-929.

DOI: 10.1038/nbt1320.


  • There are currently no refbacks.

Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.